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Human T memory stem (TSCM) cells with superior persistence capacity and effector
functions are emerging as important players in the maintenance of long-lived T-cell
memory and are thus considered an attractive population to be used in adoptive
transfer-based immunotherapy of cancer. However, the molecular signals regulating
their generation remain poorly defined. Here we show that curtailed T-cell receptor
stimulation curbs human effector CD8+ T-cell differentiation and allows the genera-
tion of CD45RO–CD45RA+CCR7+CD27+CD95+ -phenotype cells from highly purified naı¨ve
T-cell precursors, resembling naturally-occurring human TSCM. These cells proliferate
extensively in vitro and in vivo, express low amounts of effector-associated genes and
transcription factors and undergo considerable self-renewal in response to IL-15 while
retaining effector differentiation potential. Such a phenotype is associated with a lower
number of mitochondria compared to highly-activated effector T cells committed to ter-
minal differentiation. These results shed light on the molecular signals that are required
to generate long-lived memory T cells with potential application in adoptive cell transfer
immunotherapy.
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 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Specific antigen recognition by the T-cell receptor initiates a pro-
gram of clonal expansion and effector differentiation in na¨ıve
T (TN) cells that allows the migration to peripheral tissue and
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removal of infected targets [1]. Following resolution of the infec-
tion, most of these effector T cells die, leaving a population of long-
lived memory T cells that is capable of more rapid and enhanced
response following a second encounter with the pathogen [1]. The
memory T-cell compartment is highly heterogeneous [2], compris-
ing subsets that are different at the gene expression, metabolic and
epigenetic level [3]. Current models suggest that circulating mem-
ory T cells are maintained in a stem cell-like fashion, were less dif-
ferentiated cells self renew while generating more differentiated
progeny with enhanced killing capacity [4]. Such heterogeneity
C© 2017 The Authors. European Journal of Immunology published byWILEY-VCHVerlag GmbH&Co.KGaA,
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is important for anti-tumor immunity, specifically in the context
of adoptive cell transfer (ACT) immunotherapy [4]. Indeed, pre-
clinical and clinical evidence demonstrated that T cells commit-
ted to terminal differentiation, such as effector memory (TEM) or
terminal effector T (TTE) cells, are poorly effective in mediating
tumor regression following ACT [5]. Rather, less differentiated T
stem cell memory (TSCM) and central memory T (TCM) are more
potent in this regard because capable to persist in the long-term
[6–10].
The clinical use of these memory T cells has been hampered
by their limited number in the peripheral blood and at the tumor
site, thus methods have been proposed to expand the pool of
existing TSCM by homeostatic cytokines [11] or to arrest differen-
tiation of the more abundant TN precursors [8, 12–15]. TN activa-
tion with αCD3/2/28 antibody-conjugated beads in the presence
of the glycogen synthase kinase-3β (GSK-3β) inhibitor TWS119
blocked differentiation and generated CD45RO–CCR7+CD95+
TSCM-like cells with improved anti-tumor immunity [8]. However,
TWS119 decreases cell viability [12] and inhibits T-cell prolifera-
tion [8, 13]. The addition of IL-7 and IL-21 to the stimulation cock-
tail expanded the initial cell number by 6-fold and allowed to
generate naturally-occurring TSCM [14]. Similarly, IL-7 and IL-15
in combination with strong αCD3/28 stimulation (3 beads:
1 cell) induced TSCM-like cells with a hybrid CD45RO+CD45RA+
phenotype that is rarely found in vivo [13]. Nevertheless, they
were endowed with superior persistence capacity in xenogeneic
models compared to TCM and TEM. In summary, the use of specific
combinations of cytokines or inhibition of specific signaling path-
ways have been demonstrated to arrest T-cell differentiation, but
the specific role of potency of TCR stimulation as regards to the
generation of TSCM cells remains ill-defined.
Here we show that decreased TCR stimulation, achieved
either by using a low αCD3/28 bead:cell ratio or by limit-
ing the stimulation through the CD3 receptor, in the pres-
ence of IL-7 and IL-15 favors the generation of TSCM cells with
a naturally-occurring CD45RA+CD45RO– phenotype. Such dif-
ferentiation is associated with decreased T-cell activation and
expression of effector-associated transcripts and transcription
factors.
Results
Curtailed T-cell receptor stimulation in combination
with IL-7 and IL-15 generates TSCM cells
We first evaluated the effect of different cytokines, either alone or
in combination, and potency of TCR stimulation on the differen-
tiation of purified human peripheral blood TN cells (Supporting
Information Fig. 1) as assessed by surface expression of CD45RO
and CCR7. We decided to use a low (i.e., 1:2) bead:cell ratio,
as a previous report using a 3:1 ratio was associated with the
acquisition of CD45RO by differentiating TN [13]. Overall, IL-7
and IL-15 combined with αCD3/28 was the best combination to
maintain a CD45RO–CCR7+ phenotype (Fig. 1A) and to generate
bona fide CD45RO–CD45RA+CCR7+CD27+CD95+ TSCM-like cells
(Fig. 1B; hereafter referred to as iTSCM). By contrast, T-cell activa-
tion with αCD3/2/28 in the presence of IL-7/IL-15 or IL-2 prefer-
entially generated CD45RO+CCR7+ TCM-like cells (Fig. 1A and C).
The addition of IL-18 to IL-2 stimulation had limited effect on
T-cell phenotypes compared to IL-2 alone, while the addition of
IL-12generatedbonafideCD45RO+CD45RA–CCR7–CD27intCD95+
T effectors (iTEff) (Fig. 1A–B). Besides differential expression of
known T-cell differentiation markers, iTSCM also displayed lower
CD38 and HLA-DR (indicative of activation) and Ki-67 (prolifera-
tion) compared to iTEff (Fig. 1B) and had lower forward scatter
(FSC, indicative of cell size). A summary of the T-cell differen-
tiation phenotypes (defined in Materials and methods) induced
by selected culture conditions is shown in Fig. 1C. Overall, more
potent stimulation due to triggering of CD2 significantly increased
the frequency of non-viable cells at the end of the culture period,
irrespectively of the cytokine cocktail (Fig. 1D). In iTEff condition,
this was compensated by increased proliferation (Fig. 1E). Despite
the lower proliferation and activation compared to iTEff in vitro,
iTSCM cells expanded robustly over time in vivo following adoptive
transfer into NSG mice (Fig. 1F) and infiltrated multiple organs,
including the spleen, the liver and, at a lesser extent, the lung
(Fig. 1G).
Polyclonal and antigen-specific TSCM cells are
early-differentiated T cells
The capability to produce effector cytokines following TCR
stimulation is shaped by the degree of memory differentiation,
where less differentiated T cells mainly produce IL-2 and TNF
while more differentiated ones mainly produce IFN-γ [16]. We
therefore reasoned that iTSCM and iTEff had different patterns of
cytokine production. To test this, day 12 iTSCM were re-stimulated
with PMA/ionomycin (P/I) for 3 h. Figures 2A and D show that
iTSCM mainly produced TNF and IL-2, either in combination or
alone, but little IFN-γ, while iTEff were mostly characterized by
cells producing the 3 cytokines together. To confirm that the same
pattern of functionality could be observed at the antigen-specific
level, we took advantage of an accelerated DC maturation proto-
col [17] and of the elevated frequency of Mart-1-specific CD8+
T cells to generate antigen-specific TSCM cells from TN precursors.
To this end, we stimulated PBMCs from HLA-A*02+ donors with
the native, 10-mer Mart-1 peptide EAAGIGILTV, or its heteroclitic
variant ELAGIGILTV, that is capable to bind cognate TCRs with
higher avidity (hereafter named EAA and ELA, respectively).
Both peptides primed a CD8+ proliferative response, as assessed
by CFSE dilution and tetramer staining (Fig. 2B), although ELA
generated a higher frequency of antigen-specific T cells as well
as a higher total count of antigen-specific TSCM cells compared to
EAA (Fig. 2C). Subsequent ELA-peptide restimulation 7 days post
initial priming induced antigen-specific cytokine production in
both CD8+ populations (Supporting Information Fig. 3). Among
these, CD45RO–CCR7+CD95+ TSCM-phenotype cells had a simi-
lar pattern of IFN-γ, IL-2, and TNF expression, irrespectively of the
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Figure 1. Generation of iTSCM cells. (A) Representative expression of CD45RO and CCR7 in ex vivo PBMCs and in sorted CD8+ TN cells as evaluated
by flow cytometry following culture with different cytokine cocktails and T-cell receptor dependent stimulation for 11 days. Similar data were
obtained from a second donor. (B) Sorted CD8+ TN cells were cultured in αCD3/28+IL-7/15 or αCD3/2/28+IL-2/12 for 11 days and the expression
of naı¨ve and memory-associated markers in the two conditions (black line histogram and dashed line histogram, respectively; n = 4 for all
parameters, except n = 2 for Ki-67, CD38, and HLA-DR) was evaluated as in (A), by flow cytometry. Total CD8+ T cells from a healthy donor were
used as control staining (ex vivo CD8+; filled gray histogram). (C) The proportion of CD8+ T cells with the TSCM, TCM, TEM, and TTE phenotypes (gated
as in Supporting Information Fig. 1) after culture in the indicated conditions (αCD3/28+IL-7/15: n = 22; αCD3/2/28+IL-7/15: n = 9; αCD3/2/28+IL-2/12:
n = 12) for 11 days was determined by flow cytometry and shown as mean ± SEM. (D) Mean + SEM of the percentage of viable cells and (E) fold
expansion in cell number, compared to baseline, of sorted CD8+ TN cells cultured as in C. (F, G) Human CD8+ TN cells cultured in αCD3/28+IL-7/15
were transferred into NSG mice and at the indicated days after transfer, the (F) absolute numbers of CD8+ T cells in the circulation, and (G) those
cells infiltrating different organs at necropsy 32 days post transfer were evaluated by flow cytometry (see Supporting Information Fig. 2 for the
gating strategy). Data shown as mean±SEM of 5 replicate mice, one single experiment. *p < 0.05, **p < 0.01, and ***p < 0.001, Wilcoxon test.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 2. Polyclonal and antigen-specific TSCM cells are early-differentiated T cells. (A) CD8+ TN cells were activated as in Fig. 1C to generate iTSCM
and iTEff. Representative IL-2, IFN-γ and TNF expression in iTSCM cells and iTEff cells following PMA/ionomycin (P/I) stimulation was evaluated
by intracellular flow cytometry staining; ns: nonstimulated. (B) HLA-A*02+ PBMCs from healthy donors were stimulated with FLT-3, IL-1β, PGE-2
and TNF (DC maturation/activation mix, day 0) and Mart1 peptide and IL-7 and IL-15 (day 1). Representative CFSE dilution and frequency of
Mart-1-specific CD8+ T cells (top) and CD45RO and CCR7 expression in Mart-1+ cells (black) superimposed to total CD8+ T cells from the same
culture (bottom) as assessed by flow cytometry. Data shown are representative of nine other measurements from four independent experiments
(C) The frequency of Mart-1+ among CD8+ cells (left; ELA: n = 6; EAA: n = 9) and the relative TSCM count (right; ELA: n = 6; EAA: n = 5) following
peptide stimulation is shown as mean + SEM. Relative TSCM count was calculated only when the total number of cells within the Mart-1+ fraction
was >15. (D) The production of IL-2, IFN-γ and TNF following PMA/ionomycin (P/I) stimulation of cells obtained as in (A) or following ELA Mart-1
peptide stimulation of cells obtained as in (B) was measured by flow cytometry. Data shown as mean + SEM; 5 independent experiments. The
number of independent donors tested is indicated in the figure. The legend refers to the initial stimulation at day 0 and to the restimulation at day
7 (either ELA peptide or P/I). In all flow cytometry plots, values indicate percentage of cells within the gate. *p < 0.05 versus iTSCM, Wilcoxon test.
original peptide used for their generation, that was mostly
comparable to that of iTSCM generated by αCD3/28 beads and
restimulated with P/I (Fig. 2D).
iTSCM cells undergo limited activation and effector
differentiation
To gain more mechanistic insights into the differentiation of puri-
fied TN cells toward the iTSCM phenotype, we quantified the level
of molecules, either at the protein or mRNA level, that are respon-
sible for effector differentiation. Specifically, transcription factors
T-bet and Eomes control effector T-cell function [18, 19] and
increase progressively with human peripheral differentiation [8],
while IRF4 [20], IRF8 [21], and miR-155 [22] are mostly reg-
ulated by the potency of TCR activation. Accordingly, T-bet and
Eomes increased progressively with the duration of the culture
period (Fig. 3A), while IRF4, IRF8, and miR-155 were mostly
detected during the first week of culture, then their expres-
sion waned (Fig. 3B). Overall, these molecules were generally
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. iTSCM cells undergo limited activation and effector differentiation. (A, B) CD8+ TN cells were stimulated with αCD3/28+IL-7/15 (iTSCM
condition) or αCD3/2/28+IL-2/12 (iTEff condition) and evaluated for the expression of multiple effector molecules either by flow cytometry (T-bet,
Eomes, IRF4; expressed as median fluorescence intensity or MFI; n = 3) or by RT-qPCR (Irf8, miR-155; n = 4). h, hours; d, days. Data shown as
mean + SEM of the indicated numbers of samples from a single experiment. *p<0.05 versus iTSCM, Wilcoxon test. (C) Confocal microscopy analysis
(100×magnification) ofmitotracker green (stainingmitochondria; in green) and DAPI (staining nuclei; in blue) in iTSCM cells and iTEff cells generated
from CD8+ TN cells as in A. Figure shows cells from two different individuals. Similar data were obtained from two more individuals. Scale bars,
10 μM. (D) Representative flow cytometry analysis of CD45RO (top) and CD45RA (bottom) in CFSE-diluting CD8+ TN cells following stimulation
with different concentrations of plate-bound αCD3 and 5 μM soluble αCD28. (E) Heat map of data as in (D) according to CFSE generation (n = 1–4,
depending on cell count/cycle; gray box: data not available due to the low cell count).
overexpressed in iTEff vs. iTSCM throughout the stimulation period,
thus recapitulating the differential activation status observed in
Fig. 1B and indicating limited activation and effector differen-
tiation of iTSCM cells. It has also been proposed that subsets
of T cells at different stages of differentiation harbour differ-
ent numbers of mitochondria, where the mitochondrial content
increases with progressive differentiation of T cells isolated ex vivo
(TN<TCM<TEM) [23]. Single cell analysis by confocal microscopy
revealed that iTSCM harbored fewer mitochondria and appeared to
have little cytoplasm compared to iTEff (Fig. 3C), thus corroborat-
ing the lower FSC levels observed in Fig. 1B.
Despite using a low bead:cell ratio to generate TSCM with the
naturally-occurring CD45RO– CD45RA+ phenotype, it is difficult
to evaluate the specific contribution of CD3 and CD28molecules in
this regard. To this aim, we stimulated TN cells in TSCM-promoting
conditions (i.e., with IL-7 and IL-15) and in the presence of titrated
amounts of plate-bound αCD3 and soluble αCD28, then assessed
CD45RA and CD45RO expression (Fig. 3D; Supporting Informa-
tion Fig. 4). Phenotypic dynamics depend on the level of pro-
liferation [24]. As different strenghts of TCR stimulation result
in differential proliferation, analysis of specific markers was per-
formed according to the level of CFSE dilution (i.e., generations)
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. Self-renewing and multipotent capacity of iTSCM cells. (A) Ex
vivo sorted TN, TSCM, and total memory T (TMEM; defined as CD45RO+;
Supporting Information Fig. 1) CD8+ T cells as well as iTSCM (gener-
ated as in Fig. 1C) were incubated with IL-15 for 12 days (black line
histogram). CFSE dye dilution was measured by flow cytometry. Filled
gray histogram indicates unstimulated control. (B) The percentage of
CFSE-diluting cells in (A) is shown as mean±SEM of n = 4 samples
from two independent experiments (n = 2 each). *p<0.05 versus CTRL,
Wilcoxon test. (C) The frequency of TSCM-phenotype cells (defined as in
Supporting Information Fig. 1) out of total CD8+ T cells after stimula-
tion of TN cells for 6 days in iTSCM polarizing conditions (pre IL-15) or
after stimulation of the same iTSCM with IL-15 for 12 days (post IL-15)
was measured by flow cytometry. Data are shown as mean±SEM of
n = 4 samples as in B. (D) CFSE dilution (top) and CD45RO and CCR7
expression following αCD3/2/28 + IL-2 and IL-12 stimulation (bottom)
of iTSCM cells generated as in Fig. 1C was measured by flow cytome-
try. Data shown are representative of measurements made for three
samples from two independent experiments.
when >50 cells were available in each gate. Changing the con-
centration of αCD28 had no impact on T-cell phenotypes (not
shown), while decreasing αCD3 resulted in the progressive shift
of proliferating cells toward a CD45RO– CD45RA+ phenotype (Fig.
3D–E, Supporting Information Fig. 4). These cells also maintained
the expression of CCR7 and CD27 and de novo expressed CD95
(Supporting Information Fig. 4), confirming that curtailed TCR
stimulation favors the generation of TSCM cells.
Self-renewing and multipotent capacity of iTSCM cells
Naturally-occurring TSCM are known to preferentially self-renew in
vitro and in vivo compared to TCM and TEM, while simultaneously
capable to generate more differentiated progeny [8, 9, 25]. To
assess both these aspects respectively, iTSCM were collected 7 days
following stimulation, stained with CFSE and induced to prolifer-
ate in response to the homeostatic cytokine IL-15 or to αCD3/2/28
beads +IL-2 and IL-12 (iTEff-polarizing condition). According to
their memory properties, iTSCM proliferated in response to IL-15
similarly to ex vivo TSCM and bulk memory T cells (TMEM; sorted
as CD45RO+), while ex vivo TN were non-proliferating (Fig. 4A),
as previously described [8, 9, 11]. A summary of CFSE dilution
from 4 donors is shown in Fig. 4B. Similar proliferation could
be observed following iTEff-polarizing condition. While T cells in
IL-15 largely maintained their original phenotype (Fig. 4C), those
in iTEff-polarizing condition differentiated to CD45RO+CCR7+
TCM and CD45RO+CCR7– TEM cells (Fig. 4D), thus indicating self-
renewal capacity and multipotency, respectively.
Discussion
We show that curtailed T-cell receptor stimulation favors the gen-
eration of early-differentiated CD45RO– CD45RA+ TSCM cells from
na¨ıve precursors, and that this is associated with restrained T-cell
activation and upregulation of transcriptional regulators that are
otherwise responsible for effector differentiation. Similar pheno-
types could be obtained by using Dynabeads from Thermo Fisher
(data not shown), that are currently being used to expand T cells
in ACT clinical trials. Such molecular dynamics were evident since
the very first hours following stimulation in vitro. These data
are important as increasing evidence in preclinical models and
in humans indicate that T cells at earlier stages of differentiation,
such as TSCM and TCM cells are better suited to persist long-term
in vivo following adoptive transfer and are endowed with more
potent activity, such as that directed toward tumors [26].
By separately testing molecules involved in T-cell activation
and by titrating the amount of signal delivered to T cells, we found
a role for CD3, but not for CD28 in defining the acquisition of the
CD45RO– CD45RA+ TSCM phenotype. These iTSCM were both self-
renewing and multipotent and had features of early-differentiated
T cells in terms of cytokine production profile in response to poly-
clonal and antigen specific stimulation. Indeed, in vitro priming
of TN cells with the native self/tumor antigen Mart-1 EAA, and its
heteroclitic variant ELA, results in the generation of a subset of
TSCM cells with functional capacity that is similar to iTSCM gener-
ated by polyclonal stimulation. Despite priming less TN precursors
due to its decreased binding strength to the TCR, which results
in a lower total number of Mart-1-specific CD8+ T cells (Fig. 2B),
EAA selects those TCRs with the highest avidity that is in turn
associated with more pronounced anti-tumor activity [27]. It has
been therefore speculated that EAA is preferable to ELA in vac-
cine regimens. ELA/EAA peptide vaccination in combination with
CpG and Montanide in melanoma patients resulted in the early
(<3 months) generation of Mart-1-specific TSCM cells that were
capable to persist in the long term [27]. However, antigen-specific
TSCM generation was shown to occur much earlier, such as follow-
ing infection with simian immunodeficiency virus (SIV) in rhesus
macaques, where SIV-specific TSCM cells developed as early as
7 days after infection, expanded clonally and coincidentally with
the differentiation of bona fide TEff. Interestingly, a much lower
proportion of TSCM displayed expression of HLA-DR and Ki-67
activation markers compared to TEff, while preferentially express-
ing transcripts involved in T-cell survival and persistence such as
MCL1, BCL2, and LEF1 [9]. Overall, this could reflect limited TCR
stimulation occurring in vivo.
iTSCM differentiation also resulted in a lower mitochondrial
content. In line with our results, Akbar and colleagues analyzed
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human CD8+ T-cell subsets sorted ex vivo by transmission
microscopy and revealed thatmitochondrial content increases pro-
gressively in human TCM and TEM compared to TN [23]. Differently
Van der Windt et al., reported a higher mitochondrial content in
cells kept in IL-15 compared to those kept in IL-2 [28]. Differences
in protocols used to generate memory precursors could explain
these contrasting results. In fact, Van der Windt et al. generated
memory T cells by initially activating TN in the presence of IL-2 for
3 days, followed by a switch in IL-15 for 2 additional days, thus
leading to hypothesize that IL-2 stimulation, although transient,
has long term effect on T-cell metabolism. While initial exposure
to IL-2 might better mimic the in vivo condition during effector
differentiation, IL-2 stimulation in vitro should be avoided when
generating T cells for ACT, because inducing more committed dif-
ferentiation (Fig. 1A) [29], and loss of anti-tumor capacity [14].
Inhibition of effector differentiation of TN precursors has been
achieved in multiple ways, such as pharmacological intervention,
cytokine cocktails and genetic manipulation [26]. More recently,
inhibition of bromodomain and extra-terminal motif (BET) pro-
teins has been shown to limit BATF expression and favor the gen-
eration of TSCM from human TN [30]. The same group reported
similar findingswhen stimulating bulk T cells with cell-based artifi-
cial antigen-presenting cells expressing ligands for CD3 and CD28
only transiently [31]. Of note, BATF is part of a multiprotein DNA-
binding complex comprising Jun and IRF4 or IRF8 and is involved
in the generation of effector T cells [32]. Our observations suggest
that low but detectable levels of IRF4 and IRF8 are necessary for
initial T-cell activation induced by the TCR but are dispensable for
the generation of iTSCM. We propose that limiting TCR stimulation
during priming, and so the expression of transcriptional regula-
tors of effector differentiation can be exploited as an additional
strategy to generate iTSCM for ACT immunotherapy.
Materials and methods
Mice
All animal experiments were conducted upon the approval of
the Humanitas IACUC and the Italian Ministry of Health (proto-
col 256/2015-PR). NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratories), bred in SPF conditions, were used for
adoptive transfer experiments. Briefly, 1–2 × 106 CD8+ T cells,
expanded in vitro with αCD3/28-conjugated beads (T-cell activa-
tion/expansion kit, Miltenyi; 1 bead:2 cells), were co-transferred
by retrorbital injection with 8 × 106 PBMCs depleted of CD8+
T cells. For mononuclear cell isolation, tissues were minced and
filtered through a 100 μM cell strainer.
Cells
All experiments were approved by the Humanitas Research Hos-
pital IRB. Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats and frozen in liquid nitrogen according
to standard procedures.
Flow cytometry and cell sorting
Fluorochrome-conjugated monoclonal antibodies were purchased
from BD Biosciences, Biolegend and eBioscience (see Supporting
Information Table 1 for details), and titrated to determine optimal
concentration. Either fresh or frozen cells were used. Frozen cells
were thawed and stained for flow cytometry as described [11].
HLA-A*0201/MART-126-35 ELAGIGILTV tetramer staining
(conjugated to streptavidin-BV421) was performed at 37°C
for 20 min. Intracellular transcription factors were detected
following fixation of cells with the FoxP3/transcription factor
staining buffer set (eBioscience). T-cell subsets were defined
as follows: TN, CD45RO–CD45RA+CCR7+CD27+CD95–; TSCM,
CD45RO–CD45RA+CCR7+CD27+CD95+; TCM, CD45RO+CCR7+;
TEM, CD45RO+CCR7–; TTE, CD45RO–CCR7+; bulk memory
T (TMEM) cells: CD45RO+ [11]. TN were FACS-sorted as depicted
in Supporting Information Fig. 1. Samples were acquired on a
Fortessa flow cytometer or separated via a FACS Aria III cell
sorter (all from BD Biosciences). Flow cytometry data were
compensated with FlowJo (FlowJo LLC) by using single-stained
controls prepared with antibody-capture beads (BD Biosciences).
Cell culture
PBMC or sorted T cells (0.25 × 106 cells/mL) were cultured in
complete RPMI medium (10% FBS, 1% penicillin/streptomycin,
2 mM L-glutamine), and stimulated with αCD3/2/28 antibody-
coated beads. When preparing beads bound to αCD3/28 only,
the amount of αCD2 in the mix was replaced by PBS (without
calcium and magnesium, referred to as PBS−/−). Alternatively,
cells were stimulated with plate-bound αCD3 (clone OKT3) plus
soluble CD28 (clone CD28.2) in 96 flat-bottomed wells for 9
days. Human cytokines (Peprotech) were pre-titrated, then used
at 10 ng/mL unless specified. Cell proliferation was determined
by the analysis of CFSE (5 μM; Life Technologies) dilution [11].
Cells were subsequently stimulated with IL-15 (Peprotech) for 12
days at 50 ng/mL, or left in 1 ng/mL IL-15 (non-proliferating
control). Cell number was determined by Trypan blue dye
exclusion.
To induce cytokine production by PMA/ionomicin stimula-
tion and to measure intracellular cytokine production, cells were
treated as described [33].
Antigen-specific T cells were grown by using an accelerated DC
maturation protocol, as described [17]. Briefly, 3.5 × 106 CFSE-
stained PBMCs from HLA-A*02+ donors were plated in 48-well
plates in AIM-V medium (Life Technologies) additioned with FLT-
3 (50 ng/mL; DC maturation) on day 0 and with IL-1β, PGE-2,
TNF (DC activation mix) and the Melan-A/Mart1 petide vari-
ants ELAGIGLTV or EAAGIGILTV (2 μg/mL; peptide chemistry
facility, University of Lausanne) on day 1. IL-7 and IL-15 (both
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at 10 ng/mL) were included in each well on day 1. Cells were
collected at day 7 for FACS analysis, otherwise restimulated with
2 μg/mL ELAGIGLTV for 18 h in the presence of GolgiPlug (BD
Biosciences), according to manufacturer’s instructions.
Real-time PCR (qPCR)
Total RNA, purified with RNeasy Micro Kit (Qiagen), was retro-
transcribed using High-capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and analyzed by qPCR with hydrolysis
probes: IRF8 (Hs00175238 m1) and 18S (Hs99999901 s1) as
reference gene (Applied Biosystems) using the ABI 7900HT
Sequence Detection System (Applied Biosystems). For Micro-RNA
(miR) expression analysis, RNA was isolated with mirVana kit
(Ambion). Mature miR-155 and RNU44 small nucleolar RNA were
reverse transcribed with specific primers provided by Applied
Biosystems and TaqMan RT MicroRNA Kit (Applied Biosystems).
qPCR was performed with miR-155 and RNU44 specific TaqMan
primers (Applied Biosystems) and Universal PCR Master Mix, No
AmpErase R© UNG (Roche) in MicroAmp R© Fast Optical 96-Well
Reaction Plate (Applied Biosystems) on a 7500 Fast Real-Time
PCR System (Applied Biosystems). Expression levels were nor-
malized (Ct) to RNU44 or 18S endogenous controls and expres-
sion fold change relative to CD8+ TN cells were calculated using
2– (Ct sample- Ct naive) formula.
Confocal microscopy
CD8+ T cells were washed in PBS−/− and incubated with 1 mL
of pre-warmed Mitotracker Green (25nM prepared in PBS−/−) for
30 min at 37°C. To allow T-cell adhesion, slides were previously
incubated for 30 min with 0.02% polylisin and coated for 3 h
at 37°C with αCD3 (OKT3 clone, BD Biosciences; 10 μg/mL in
PBS−/−) and αCD28 (CD28.2 clone, BD Biosciences; μg/mL in
PBS−/−) followed by 3 washes in PBS−/−. T cells (0.15 × 106)
were then layered on slides and incubated for 15 min at 37°C.
After incubation, cells were fixed with 4% PFA for 10 min, washed
twice with 2% BSA in PBS+/+ and once with 2% BSA, 0.05% tween
in PBS+/+. To identify nuclei, cells were counterstained with DAPI
(Invitrogen) by incubating for 10’ at RT. Slides were acquired with
an FV1000 confocal microscope (Olympus). Images were analyzed
with ImageJ (NIH).
Statistical analysis
Analysis was performed using GraphPad PRISM (6.0b) and SPICE
5.22 software. Non-parametric paired or unpaired Wilcoxon rank
test were used to compare two groups. P values are two-sided and
were considered significant when 0.05.
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